[Tag 72: a new tumor-associated antigen identified by a monoclonal antibody].
In order to evaluate the usefulness of Tag 72--tumor associated antigen assay--in gastroenterology, we have studied with Ca 72-4 radioimmunoassay (Centocor) 551 patients suffering benign (233) and neoplastic (318) gastrointestinal diseases and 205 normal controls. The cut-off point was fixed at 6 U/ml. Only in gastric cancers, the Tag 72 assay, with the proposed method, provide additional information in this pathology (sensitivity 30%, specificity 98.7%). The most striking observation to be made from the current study is a poor sensitivity of the test for gastrointestinal cancers, but rather the excellent specificity of the Ca 72-4 IRMA with respect to benign gastrointestinal diseases. The sensitivity of Ca 72-4 assay, vs Ca 19-9 and CEA, for the same diseases, is less, but specificity is better.